Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...
Medicare GLP-1 Bridge provides Wegovy to eligible beneficiaries for $50/month through 2027, creating a defined access channel for obesity treatment previously largely excluded from Medicare coverage.
QuantumCell received worldwide rights to NeuroRestore/ACD856, with closing contingent on foreign direct investment approvals in Sweden and Denmark under customary regulatory conditions. Financial ...
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results